Trials / Not Yet Recruiting
Not Yet RecruitingNCT07379151
Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine
Evaluation of the Antibody Persistence in African Participants Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 450 (estimated)
- Sponsor
- Serum Institute of India Pvt. Ltd. · Industry
- Sex
- All
- Age
- 7 Years – 36 Years
- Healthy volunteers
- Accepted
Summary
This study will measure immune persistence of the NmCV-5 more than 5 years after a single dose vaccination in participants 2-29 years of age in Mali and The Gambia.
Detailed description
This non-interventional long-term follow-up study will involve one telephonic contact in all 1800 former participants from study ACYWX-03 followed by one visit beyond five years after vaccination in a subset of 450 participants. This subset will be randomly selected to participate in a follow-on immune persistence evaluation. To document the duration of the immune response and any requirement of booster dose in the target population, this study is intended to explore antibody persistence.
Conditions
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2026-01-30
- Last updated
- 2026-02-04
Source: ClinicalTrials.gov record NCT07379151. Inclusion in this directory is not an endorsement.